Filings & corporate actions
77 results filed
CSVNext results · Q2 FY27
Expected 28 Oct 2026 – 12 Nov 2026
Estimate: filed 28–43 days after quarter end, last 5 times
Dividend
₹75.00 per share · last 17 Jul 2026
2026
- 28 JulresultsResults · Q1 FY27 · standalone+0.9%NSE
- 17 JuldividendDividend · ₹75.00 per share-2.8%
- 16 JulshareholdingShareholding · 30 Jun 2026-0.1%NSE
- 12 MayresultsResults · Q4 FY26 · standalone-2.4%NSE
- 15 AprshareholdingShareholding · 31 Mar 2026+0.9%NSE
- 9 FebresultsResults · Q3 FY26 · standalone+4.1%NSE
- 16 JanshareholdingShareholding · 31 Dec 2025-1.2%NSE
Reaction to results · all yearsrose on day 0 in 35 of 77 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 28 Jul 2026 | +0.9% | +4.2% | +1.9% | 1.4× |
| Q4 FY26 | 12 May 2026 | -2.4% | -0.8% | -3.2% | 1.9× |
| Q3 FY26 | 9 Feb 2026 | +4.1% | +6.1% | -1.3% | 88.6× |
| Q2 FY26 | 12 Nov 2025 | +0.6% | +0.3% | -0.2% | 12.5× |
| Q1 FY26 | 13 Aug 2025 | +4.3% | +11.0% | +1.1% | 23.7× |
| Q4 FY25 | 20 May 2025 | +0.6% | +11.3% | +17.0% | 1.6× |
| Q3 FY25 | 31 Jan 2025 | +0.5% | -4.0% | -13.2% | 0.5× |
| Q2 FY25 | 28 Oct 2024 | -1.4% | -0.3% | +0.7% | 0.4× |
| Q1 FY25 | 29 Jul 2024 | +4.0% | +7.9% | +11.0% | 4.1× |
| Q4 FY24 | 17 May 2024 | +1.6% | +3.4% | +8.2% | 0.6× |
| Q3 FY24 | 9 Feb 2024 | 0.0% | +5.6% | +1.0% | 0.9× |
| Q2 FY24 | 28 Oct 2023 | +0.2% | -0.6% | +3.2% | 1.1× |
| Q1 FY24 | 11 Aug 2023 | -3.0% | -1.5% | -3.1% | 1.9× |
| Q4 FY23 | 15 May 2023 | 0.0% | +0.5% | +0.9% | 4.8× |
| Q3 FY23 | 9 Feb 2023 | +2.9% | 0.0% | -4.0% | 2.5× |
| Q2 FY23 | 11 Nov 2022 | +3.9% | +2.1% | +2.2% | 5.4× |
| Q1 FY23 | 5 Aug 2022 | -0.7% | +1.2% | +2.8% | 4.6× |
| Q4 FY22 | 20 May 2022 | +1.3% | -1.8% | -5.7% | 1.8× |
| Q3 FY22 | 3 Feb 2022 | -2.1% | -2.6% | -6.6% | 6.9× |
| Q2 FY22 | 3 Nov 2021 | -0.3% | +2.2% | -3.9% | 0.2× |
| Q1 FY22 | 28 Jul 2021 | +0.1% | -1.8% | -5.2% | 5.3× |
| Q4 FY21 | 26 May 2021 | -2.6% | -1.4% | +4.7% | 1.4× |
| Q3 FY21 | 5 Feb 2021 | -0.4% | +1.1% | +3.1% | 1.0× |
| Q2 FY21 | 2 Nov 2020 | 0.0% | -1.2% | +4.9% | 1.5× |
| Q1 FY21 | 27 Jul 2020 | -1.2% | +0.2% | +10.0% | 1.5× |
| Q4 FY20 | 15 Jun 2020 | -0.6% | -2.2% | +2.4% | 0.8× |
| Q3 FY20 | 14 Feb 2020 | -8.6% | -9.4% | -8.9% | 7.2× |
| Q2 FY20 | 26 Oct 2019 | +12.4% | +16.1% | +14.2% | 6.3× |
| Q1 FY20 | 9 Aug 2019 | +3.2% | +1.5% | +13.0% | 10.2× |
| Q4 FY19 | 28 May 2019 | -3.3% | -4.9% | -0.3% | 1.9× |
| Q3 FY19 | 31 Jan 2019 | +0.1% | +0.9% | +8.6% | 0.5× |
| Q2 FY19 | 22 Nov 2018 | -0.8% | -3.6% | +0.8% | 0.3× |
| Q1 FY19 | 10 Aug 2018 | +4.5% | +9.3% | +31.8% | 1.7× |
| Q4 FY18 | 7 Jun 2018 | +2.5% | +0.5% | -1.0% | 0.8× |
| Q3 FY18 | 30 Jan 2018 | +0.2% | -4.6% | -0.6% | 0.5× |
| Q2 FY18 | 21 Nov 2017 | -0.5% | -3.8% | +2.5% | 0.9× |
| Q1 FY18 | 31 Jul 2017 | +0.7% | +1.5% | +2.0% | 0.7× |
| Q4 FY17 | 22 May 2017 | -0.1% | -4.4% | +0.7% | 2.6× |
| Q3 FY17 | 2 Feb 2017 | -0.6% | -2.9% | -3.0% | 0.8× |
| Q2 FY17 | 7 Nov 2016 | -0.1% | +0.6% | +3.9% | 0.6× |
| Q1 FY17 | 3 Oct 2016 | -1.1% | -0.9% | -8.2% | 0.6× |
| Q4 FY16 | 6 May 2016 | +0.2% | -0.1% | +3.7% | 3.7× |
| Q3 FY16 | 8 Feb 2016 | -1.3% | -10.4% | -13.7% | 0.4× |
| Q2 FY16 | 10 Nov 2015 | +0.1% | -2.2% | -1.1% | 2.6× |
| Q1 FY16 | 27 Jul 2015 | -0.2% | +8.9% | +3.4% | 1.5× |
| Q4 FY15 | 7 May 2015 | +1.0% | -0.2% | -3.1% | 0.6× |
| Q3 FY15 | 18 Feb 2015 | -0.4% | -2.3% | +5.7% | 0.8× |
| Q2 FY15 | 11 Nov 2014 | -0.8% | +2.0% | +20.2% | 0.8× |
| Q1 FY15 | 24 Jul 2014 | -2.3% | -6.1% | -0.5% | 0.9× |
| Q4 FY14 | 5 May 2014 | -0.9% | -1.7% | -2.3% | 0.4× |
| Q3 FY14 | 5 Feb 2014 | 0.0% | +1.8% | +12.6% | 0.6× |
| Q2 FY14 | 15 Nov 2013 | +2.9% | +29.9% | -6.2% | 3.2× |
| Q1 FY14 | 8 Aug 2013 | -0.1% | -1.3% | -1.2% | 0.4× |
| Q4 FY13 | 18 May 2013 | +1.4% | -1.9% | +2.3% | 0.8× |
| Q3 FY13 | 8 Feb 2013 | -0.6% | -4.4% | -7.7% | 0.5× |
| Q2 FY13 | 9 Nov 2012 | -0.2% | -1.3% | +2.1% | 2.8× |
| Q1 FY13 | 24 Aug 2012 | +0.4% | +4.4% | +0.5% | 0.7× |
| Q4 FY12 | 22 May 2012 | -1.6% | -2.3% | -6.4% | 0.3× |
| Q3 FY12 | 30 Jan 2012 | -3.6% | -3.2% | -1.7% | 0.6× |
| Q2 FY12 | 24 Oct 2011 | -0.9% | -2.8% | -12.8% | 6.1× |
| Q1 FY12 | 1 Aug 2011 | -0.1% | -7.5% | -9.8% | 3.1× |
| Q3 FY11 | 11 Jan 2011 | +4.9% | +11.7% | +6.8% | 19.3× |
| Q2 FY11 | 6 Oct 2010 | -2.7% | -1.3% | +0.5% | 1.8× |
| Q1 FY11 | 12 Jul 2010 | +2.0% | +7.5% | -4.7% | 1.0× |
| Q4 FY10 | 26 Mar 2010 | -0.1% | +5.1% | +8.3% | 2.0× |
| Q3 FY10 | 25 Feb 2010 | +0.1% | +1.6% | +3.4% | 1.0× |
| Q2 FY10 | 29 Sept 2009 | +0.2% | -0.3% | +0.9% | 1.8× |
| Q1 FY10 | 27 Jun 2009 | 0.0% | -4.3% | -4.4% | 2.5× |
| Q4 FY09 | 30 Mar 2009 | +4.1% | +7.1% | +28.2% | 1.4× |
| Q3 FY09 | 30 Jan 2009 | -2.1% | -0.5% | -3.0% | 0.3× |
| Q2 FY09 | 30 Sept 2008 | +5.3% | +3.3% | -11.9% | 4.7× |
| Q1 FY09 | 30 Jun 2008 | -0.6% | -2.3% | -1.9% | 1.0× |
| Q4 FY08 | 31 Mar 2008 | +3.5% | +3.6% | -1.0% | 1.7× |
| Q3 FY08 | 25 Feb 2008 | 0.0% | +4.0% | +1.0% | 2.6× |
| Q2 FY08 | 24 Sept 2007 | +2.0% | +4.9% | -0.3% | 3.3× |
| Q1 FY08 | 28 Jun 2007 | +1.8% | -0.4% | -3.3% | 2.6× |
| Q4 FY07 | 22 Mar 2007 | -0.2% | +10.3% | +15.1% | 1.4× |
| Average | +0.4% | +1.1% | +1.3% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+8.3%
Profit YoY+6.6%
Interest cost YoY+14.6%
Revenue QoQ+3.8%
Profit QoQ+2.3%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +19.4% | +10.3% | +6.6% | +5.1% | +6.9% | +6.0% |
| Profit | +23.4% | +10.6% | +20.1% | +10.1% | +10.1% | +10.9% |
Key data
CSVOpen3,860.00
Day range3,826.70 – 3,868.20
52-week range3,792.10 – 5,578.50
From 52w high-30.9%
RSI (14)19.8
ATR (14)86.78
Volume21.0K
Avg volume (20D)64.6K
Rel volume0.33×
Volatility (1Y)23.5%
Turnover₹8.1Cr
SMA 50 / 2004,503.90 / 4,690.29
Delivery percentage
Latest · 6 Oct 202667.9%
20-day avg53.4%
1-year avg54.1%
Percentile (own history)89th
Range4.2–97.9%
Sessions1,731
Over the last 20 sessions PFIZER settled 53.4% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 54.1%. The latest session ranks higher than 89% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.26% | -2.92% | -17.04% | -15.13% | -21.18% | -21.88% |
Valuation
CSVMarket cap₹17,623 Cr
P/E (TTM)19.0
EPS (TTM)202.61
Shares outstanding4.58Cr
Listed28 Apr 1999
Ownership
CSVPromoter63.92%
Promoter Δ QoQ0.00 pp
Public36.08%
FII1.65%
DII17.80%
Pledged0.00%
Quarterly results · standalone
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,245.4 | 645.0 | 629.2 | 653.2 |
| YoY chg | +111.6% | +19.9% | +6.3% | +8.3% |
| Net profit (₹ Cr) | 380.8 | 141.8 | 199.8 | 204.5 |
| YoY chg | +140.5% | +11.2% | -39.6% | +6.6% |
| Net margin | 30.6% | 22.0% | 31.8% | 31.3% |
| EPS | 0.00 | 31.01 | 43.68 | 44.69 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 63.92% · public 36.08%2021-092026-06
- Promoter
- Public and others
- Promoter
- 63.92%
- Public
- 36.08%
- Promoter change
- 0.00 pp
- Filed
- 16 Jul 2026
- FII
- 1.65%
- DII
- 17.80%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSVStandalone
₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 575.2 | 540.0 | 546.6 | 562.9 | 588.6 | 538.0 | 591.9 | 603.1 | 1,245.4 | 645.0 | 629.2 | 653.2 | |
| Other income | 36.1 | 35.9 | 75.1 | 41.8 | 43.1 | 42.8 | 44.6 | 67.2 | 109.0 | 38.2 | 40.7 | 44.8 | |
| Total income | 611.3 | 575.8 | 621.8 | 604.7 | 631.7 | 580.8 | 636.5 | 670.2 | 1,354.4 | 683.2 | 670.0 | 698.0 | |
| Total expenses | 410.8 | 407.8 | 377.9 | 402.1 | 416.4 | 408.3 | 383.5 | 410.7 | 839.5 | 433.1 | 410.2 | 421.3 | |
| └ Finance costs | 2.7 | 2.9 | 7.0 | 2.1 | 2.1 | 1.5 | 2.7 | 3.3 | 5.4 | 2.0 | 2.1 | 1.5 | |
| └ Depreciation | 15.4 | 17.6 | 13.8 | 14.6 | 15.0 | 14.8 | 16.4 | 14.4 | 28.7 | 14.3 | 14.8 | 14.3 | |
| Profit before tax | 200.5 | 175.9 | 243.9 | 202.6 | 215.2 | 172.4 | 425.8 | 259.5 | 514.9 | 192.0 | 268.8 | 276.7 | |
| Tax expense | 51.6 | 46.0 | 65.0 | 51.9 | 56.9 | 44.8 | 94.9 | 67.8 | 134.1 | 50.1 | 69.0 | 72.2 | |
| Net profit | 149.0 | 130.0 | 178.9 | 150.7 | 158.4 | 127.6 | 330.9 | 191.8 | 380.8 | 141.8 | 199.8 | 204.5 | |
| EPS | 32.56 | 27.12 | 22.33 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 83.23 | 31.01 | 43.68 | 44.69 | |
| Net margin | 25.90% | 24.07% | 32.72% | 26.78% | 26.90% | 23.72% | 55.91% | 31.80% | 30.57% | 21.99% | 31.76% | 31.30% | |
| PBT margin | 34.86% | 32.58% | 44.61% | 36.00% | 36.57% | 32.05% | 71.94% | 43.04% | 41.34% | 29.76% | 42.72% | 42.36% | |
| Tax rate | 25.71% | 26.12% | 26.65% | 25.62% | 26.43% | 26.00% | 22.28% | 26.12% | 26.05% | 26.11% | 25.67% | 26.10% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 28 Jul 2026.
PFIZER at a glance
- PFIZER closed at ₹3,852.2 on 6 Oct 2026, +0.26% on the day, -21.9% over one year, 30.9% below its 52-week high of ₹5,578.5.
- Delivery was 67.9% of traded quantity on 6 Oct 2026, the 89th percentile of its own 1,731 sessions with a reading (20-session average 53.4%, 1-year average 54.1%).
- Market capitalisation is ₹17,623 crore at a trailing P/E of 19.0 (trailing EPS ₹202.61).
- Q1 FY27 results (standalone, filed 28 Jul 2026): revenue ₹653 crore (+8.3% year on year), net profit ₹204 crore (+6.6%); the price moved +0.9% on the first session after.
- Promoters held 63.92% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 28 Oct 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE182A01018
SeriesEQ
Listed28 Apr 1999
History from4 Jan 1995
Sessions7,824
Turnover rank#674
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE